Showing 2391-2400 of 3016 results for "".
- Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removalhttps://practicaldermatology.com/news/sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal/2459899/Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red
- Stelatopia Emollient Face Cream Now Available from Mustelahttps://practicaldermatology.com/news/stelatopia-emollient-face-cream-now-available-from-mustela/2459902/Mustela Stelatopia Emollient Face Cream is now available, specifically designed for extremely dry to eczema-prone skin and gentle enough to use on newborns. Formulated with Avocado Perseose®, which is intended to restore and protect the skin barrier by boosting ceramides a
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- 2019 Residents of Distinction Return from Caribbean Dermatology Symposiumhttps://practicaldermatology.com/news/2019-residents-of-distinction-return-from-caribbean-dermatology-symposium/2459919/Five dermatology residents have just returned from the 18th Annual Caribbean Dermatology Symposium, held in Grand Cayman Island. Their participation was sponsored by Beiersdorf Inc., as part of the dermMentors™ Resident of Distinction Award™ program. The reside
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea
- #RealDealAesthetics Takes on Minimally Invasive Body Contouringhttps://practicaldermatology.com/news/realdealaesthetics-takes-on-minimally-invasive-body-contouring/2459934/Save the date: Practical Dermatology®'s sister publication Modern Aesthetics’ newest Tweet chat series -- #RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD is back. The f
- Study: States with Fewer Melanoma Diagnoses Have Higher Death Rateshttps://practicaldermatology.com/news/study-states-with-fewer-melanoma-diagnoses-have-higher-death-rates/2459937/States with fewer melanoma diagnoses actually have higher death rates, report researchers at University of Utah Health. The researchers conducted a state-by-state analysis to understand the geographic disparities for patients diagnosed with melanoma. They found lower survival is associate
- L'Occitane to Buy ELEMIS for $900 Millionhttps://practicaldermatology.com/news/loccitane-to-buy-elemis-for-900-million/2459939/L’Occitane International S.A. has entered into a definitive agreement to acquire ELEMIS, the number one luxury British skincare brand, for $900 million in cash. ELEMIS is being sold by Steiner Leisure Limited. Reinold Geiger, Chairman and Chief Executive Officer of L’OCCITANE
- “Christmas Berry” Plant Compound Could Fight Uveal Melanomahttps://practicaldermatology.com/news/christmas-berry-plant-compound-could-fight-uveal-melanoma/2459945/A compound extracted from the Christmas berry primrose plant may stops the growth of uveal melanoma, according to preliminary tests. With further testing, the discovery could lead to new therapeutic options for patients with uveal melanoma, report researches from the